Is Gilteritinib an alk inhibitor?

Gilteritinib (Gilteritinib) is not an ALK (Anaplastic Lymphoma Kinase, non-lymphoma kinase) inhibitor. Its main role is to target the FLT3 (FMS-like tyrosine kinase 3) receptor tyrosine kinase and is used to treat FLT3 mutation-positive acute myeloid leukemia (AML).

ALKinhibitors are commonly used to treat some other types of cancer, particularly cancers such as non-small cell lung cancer and neuroblastoma, in which mutations in the ALK gene play a key role. Giritinib and ALK inhibitors have different mechanisms of action and therapeutic indications and therefore they should not be confused. Giritinib is primarily used to treat FLT3 mutation-positive AML, while ALK inhibitors are used to treat other cancer types.

Giritinib is currently on the market in China, but it is not included in medical insurance. If patients need it, they can go to the hospital to buy it at their own expense, but the price is very high, about about 35,000 yuan. For specific prices, please consult the local hospital pharmacy. Foreign original drugs of gilitinib are even more expensive. For example, the price of the Hong Kong version of the original drug is around 90,000 yuan, and the European version of the original drug is as high as more than 200,000 yuan, which is simply unaffordable for ordinary patients. But what is gratifying is that there are already foreign generic drugs of giritinib, mainly Laotian generic drugs. The price is about four to five thousand yuan, which is relatively cheap. In terms of drug ingredients, the ingredients of domestic and foreign original gilitinib drugs are basically the same as those of generic drugs.